Program
Investigational COVID-19 Vaccine Lot A
Also written as “Investigational COVID-19 Vaccine Lot B”.
Its studies are mostly in Influenza, Human, led by Moderna.
Furthest: phase 2, since Mar 5, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moderna | 10 open or running | phase 2since Mar 5, 2025 | Mar 5, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 5, 2025First study: phase 2 study in Influenza, HumanFirst studyNCT06864143 · 1,320 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Investigational COVID-19 Vaccine Lot A”name, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06864143Influenza, Human · United States | 2 | Completed | Oct 13, 2025 | 1,320 |
How it is read
Names in the registry
- “Investigational COVID-19 Vaccine Lot A”, 1 entry
- “Investigational COVID-19 Vaccine Lot B”, 1 entry
Conditions, from the studies’ own filings
- Influenza, Human, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.